ADAURA, a Bridge Connecting Disease Control with Long-term Survival

Jing Zhao^{1

2}, Rui Jin¹, Lingxiao Zhou¹, Yang Xia¹, Wen Li¹

Affiliations

¹ Key Laboratory of Respiratory Disease of Zhejiang Province, Department of Respiratory and Critical Care Medicine, 89681Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
² Department of Medical Oncology, 89681Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.

Comment

Jing Zhao et al. Sci Prog. 2021 Oct.

. 2021 Oct;104(4):368504211050289.

doi: 10.1177/00368504211050289.

Jing Zhao^{1

2}, Rui Jin¹, Lingxiao Zhou¹, Yang Xia¹, Wen Li¹

¹ Key Laboratory of Respiratory Disease of Zhejiang Province, Department of Respiratory and Critical Care Medicine, 89681Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
² Department of Medical Oncology, 89681Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.

No abstract available

Comment on

Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study.
Zhong WZ, Wang Q, Mao WM, Xu ST, Wu L, Shen Y, Liu YY, Chen C, Cheng Y, Xu L, Wang J, Fei K, Li XF, Li J, Huang C, Liu ZD, Xu S, Chen KN, Xu SD, Liu LX, Yu P, Wang BH, Ma HT, Yan HH, Yang XN, Zhou Q, Wu YL; ADJUVANT investigators. Zhong WZ, et al. Lancet Oncol. 2018 Jan;19(1):139-148. doi: 10.1016/S1470-2045(17)30729-5. Epub 2017 Nov 21. Lancet Oncol. 2018. PMID: 29174310 Clinical Trial.
SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer.
Pennell NA, Neal JW, Chaft JE, Azzoli CG, Jänne PA, Govindan R, Evans TL, Costa DB, Wakelee HA, Heist RS, Shapiro MA, Muzikansky A, Murthy S, Lanuti M, Rusch VW, Kris MG, Sequist LV. Pennell NA, et al. J Clin Oncol. 2019 Jan 10;37(2):97-104. doi: 10.1200/JCO.18.00131. Epub 2018 Nov 16. J Clin Oncol. 2019. PMID: 30444685 Free PMC article. Clinical Trial.

1. Wu YL, Tsuboi M, He J, et al.. Osimertinib in resected EGFR-mutated Non-small-cell lung cancer. N Engl J Med 2020; 383: 1711–1723. - PubMed
1. Wu YL, John T, Grohe C, et al.. Postoperative chemotherapy use and outcomes from ADAURA: osimertinib as adjuvant therapy for resected EGFR mutated NSCLC. J Thorac Oncol 2021; 16: S113–S114. - PubMed
1. Pennell NA, Neal JW, Chaft JE, et al.. SELECT: a phase II trial of adjuvant erlotinib in patients With resected epidermal growth factor receptor-mutant Non-small-cell lung cancer. J Clin Oncol 2019; 37: 97–104. - PMC - PubMed
1. Zhong WZ, Wang Q, Mao WM, et al.. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study. Lancet Oncol 2018; 19: 139–148. - PubMed
1. Zhou C, Wu YL, Chen G, et al.. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011; 12: 735–742. - PubMed